Editorial
Lung cancer susceptibility beyond smoking history: opportunities and challenges
Translational Lung Cancer Research
2022;
11
(7)
:1230-1232
.
(28 July 2022)
Unarranged territory in uncommon EGFR mutations
Translational Lung Cancer Research
2022;
11
(7)
:1233-1236
.
(28 July 2022)
From expert recommendations to multidisciplinary team decisions: a way to set out the novel perioperative options for patients with non-small-cell lung cancer
Translational Lung Cancer Research
2022;
11
(7)
:1237-1240
.
(28 July 2022)
Resectable non-small cell lung cancer: an evolving landscape
Translational Lung Cancer Research
2022;
11
(7)
:1241-1246
.
(28 July 2022)
Consensus
Expert consensus on perioperative treatment for non-small cell lung cancer
Translational Lung Cancer Research
2022;
11
(7)
:1247-1267
.
(28 July 2022)
Original Article
Peripheral blood leukocyte mitochondrial DNA content and risk of lung cancer
Translational Lung Cancer Research
2022;
11
(7)
:1268-1278
.
(28 July 2022)
Prognosis and recurrence patterns in patients with early stage lung cancer: a multi-state model approach
Translational Lung Cancer Research
2022;
11
(7)
:1279-1291
.
(28 July 2022)
Preclinical evaluation of thin convex probe endobronchial ultrasound-guided transbronchial needle aspiration for intrapulmonary lesions
Translational Lung Cancer Research
2022;
11
(7)
:1292-1301
.
(28 July 2022)
Causal effects of genetically determined metabolites on cancers included lung, breast, ovarian cancer, and glioma: a Mendelian randomization study
Translational Lung Cancer Research
2022;
11
(7)
:1302-1314
.
(28 July 2022)
Increased serum levels of KiSS1-derived peptides in non-small cell lung cancer patient liquid biopsies and biological relevance
Translational Lung Cancer Research
2022;
11
(7)
:1315-1326
.
(28 July 2022)
Various recurrence dynamics for non-small cell lung cancer depending on pathological stage and histology after surgical resection
Translational Lung Cancer Research
2022;
11
(7)
:1327-1336
.
(28 July 2022)
Comprehensive analysis of mutational profile and prognostic significance of complex glandular pattern in lung adenocarcinoma
Translational Lung Cancer Research
2022;
11
(7)
:1337-1347
.
(28 July 2022)
Racial disparities in histological subtype, stage, tumor grade and cancer-specific survival in lung cancer
Translational Lung Cancer Research
2022;
11
(7)
:1348-1358
.
(28 July 2022)
Phase II study of nanoparticle albumin-bound paclitaxel monotherapy for relapsed non-small cell lung cancer with patient-reported outcomes (NLCTG1302)
Translational Lung Cancer Research
2022;
11
(7)
:1359-1368
.
(28 July 2022)
Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22
Translational Lung Cancer Research
2022;
11
(7)
:1369-1379
.
(28 July 2022)
Identification and validation of a ferroptosis-related prognostic risk-scoring model and key genes in small cell lung cancer
Translational Lung Cancer Research
2022;
11
(7)
:1380-1393
.
(28 July 2022)
Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study
Translational Lung Cancer Research
2022;
11
(7)
:1394-1404
.
(28 July 2022)
BARX2/FOXA1/HK2 axis promotes lung adenocarcinoma progression and energy metabolism reprogramming
Translational Lung Cancer Research
2022;
11
(7)
:1405-1419
.
(28 July 2022)
Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study
Translational Lung Cancer Research
2022;
11
(7)
:1420-1433
.
(28 July 2022)
Proteomic analysis of plasma exosomes in patients with non-small cell lung cancer
Translational Lung Cancer Research
2022;
11
(7)
:1434-1452
.
(28 July 2022)
The extent of mediastinal lymph node dissection correlates with survival of small cell lung cancer patients after resection: a propensity score-matched cohort study analysis
Translational Lung Cancer Research
2022;
11
(7)
:1453-1467
.
(28 July 2022)
Comparison of perioperative outcomes among non-small cell lung cancer patients with neoadjuvant immune checkpoint inhibitor plus chemotherapy, EGFR-TKI, and chemotherapy alone: a real-world evidence study
Translational Lung Cancer Research
2022;
11
(7)
:1468-1478
.
(28 July 2022)
Identification of a three-gene expression signature and construction of a prognostic nomogram predicting overall survival in lung adenocarcinoma based on TCGA and GEO databases
Translational Lung Cancer Research
2022;
11
(7)
:1479-1496
.
(28 July 2022)
Case Report
Anti-Zic4 paraneoplastic cerebellar degeneration in a patient with EGFR-mutated NSCLC: a case report
Translational Lung Cancer Research
2022;
11
(7)
:1497-1502
.
(28 July 2022)
Study Protocol
Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a prospective longitudinal biomarker study
Translational Lung Cancer Research
2022;
11
(7)
:1503-1509
.
(28 July 2022)
Letter to the Editor
NRF2-pathway mutations predict radioresistance in non-small cell lung cancer
Translational Lung Cancer Research
2022;
11
(7)
:1510-1513
.
(28 July 2022)
Shift in lung cancer stage at diagnosis during the COVID-19 pandemic in New York City
Translational Lung Cancer Research
2022;
11
(7)
:1514-1516
.
(28 July 2022)
